Brokerages Set Celcuity, Inc. (NASDAQ:CELC) PT at $105.25

Celcuity, Inc. (NASDAQ:CELC) has been assigned an average rating of “Moderate Buy” from the ten research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $105.25.

CELC has been the subject of a number of recent analyst reports. Wells Fargo & Company initiated coverage on shares of Celcuity in a report on Friday, December 12th. They issued an “overweight” rating and a $126.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, January 21st. Wolfe Research initiated coverage on Celcuity in a research note on Tuesday, November 18th. They issued an “outperform” rating and a $110.00 price target for the company. Jefferies Financial Group upped their price target on Celcuity from $108.00 to $134.00 and gave the stock a “buy” rating in a report on Tuesday, December 2nd. Finally, HC Wainwright reissued a “neutral” rating and issued a $94.00 price objective (up from $77.00) on shares of Celcuity in a report on Monday, November 17th.

Insider Buying and Selling

In other Celcuity news, Director Richard E. Buller sold 3,000 shares of the company’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $105.69, for a total transaction of $317,070.00. Following the completion of the transaction, the director directly owned 6,760 shares in the company, valued at approximately $714,464.40. This represents a 30.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director David Dalvey sold 20,000 shares of the stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the transaction, the director directly owned 90,000 shares in the company, valued at approximately $10,802,700. The trade was a 18.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 15.77% of the company’s stock.

Institutional Trading of Celcuity

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Avoro Capital Advisors LLC acquired a new stake in Celcuity in the 4th quarter worth about $310,302,000. NEA Management Company LLC boosted its stake in shares of Celcuity by 64.9% in the fourth quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock worth $352,637,000 after acquiring an additional 1,391,300 shares during the last quarter. State Street Corp increased its position in shares of Celcuity by 126.6% during the fourth quarter. State Street Corp now owns 1,637,687 shares of the company’s stock worth $163,343,000 after purchasing an additional 914,887 shares in the last quarter. Apis Capital Advisors LLC acquired a new position in Celcuity in the 3rd quarter valued at $38,334,000. Finally, UBS Group AG lifted its holdings in Celcuity by 910.1% in the 3rd quarter. UBS Group AG now owns 854,483 shares of the company’s stock valued at $42,211,000 after purchasing an additional 769,891 shares in the last quarter. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Price Performance

Shares of NASDAQ CELC opened at $104.79 on Thursday. The company has a debt-to-equity ratio of 2.74, a current ratio of 12.26 and a quick ratio of 12.26. The stock has a market capitalization of $4.85 billion, a price-to-earnings ratio of -28.55 and a beta of 0.36. The firm’s 50 day simple moving average is $105.68 and its 200-day simple moving average is $80.57. Celcuity has a 12 month low of $7.57 and a 12 month high of $120.32.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.